Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-04-17 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
2023年度财务审计报告
Audit Report / Information Classification · 95% confidence The document is a standalone auditor’s report issued by Tianheng Certified Public Accountants for Jiangsu Senxuan Pharmaceutical Co., Ltd. covering the 2023 consolidated and parent company financial statements, including the audit opinion, basis, key audit matters, auditor and management responsibilities, signatures, and full financial schedules. This matches the definition of a standalone Audit Report/Information (AR) rather than a full Annual Report (10-K) or mere announcement. FY 2023
2024-04-17 Chinese
2023年年度权益分派预案暨落实“提质守信重回报”行动公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a 2023 annual equity distribution plan and announcement of implementing a shareholder return action. It details the company's profit distribution proposal for 2023, including cash dividends per share, total dividend amount, and references to the audited 2023 annual report. It also includes the board and supervisory committee's approval and opinions, the company's articles of association on profit distribution, and mentions that the proposal still requires shareholder meeting approval. The document is focused on dividend distribution plans and related corporate governance procedures rather than the full annual report or financial statements. It is not a simple announcement of a report publication but a substantive announcement of dividend amount and plan. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is 2093 characters, which is consistent with a detailed dividend announcement rather than a full annual report or other report types.
2024-04-17 Chinese
关于使用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the use of its own idle funds for cash management by purchasing short-term financial products. It details the purpose, amount, duration, decision-making process, risk analysis, and impact on the company. The document includes resolutions from the board and supervisory committee meetings and is dated April 18, 2024. The content is focused on a financing activity related to the company's capital management rather than a full financial report, earnings release, or regulatory filing. The document length is short (1580 characters), and it is not a report publication announcement or certification. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2024-04-17 Chinese
高级管理人员年薪考核细则
Governance Information Classification · 95% confidence The document is a detailed announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the salary assessment rules for senior management personnel. It includes specific principles, salary structures, performance evaluation methods, and payment management for senior executives. The content focuses on governance and internal management policies related to executive compensation rather than financial results, audit opinions, or shareholder voting outcomes. There is no indication that this is a full annual report, audit report, earnings release, or any other financial report. Instead, it is a governance-related document detailing internal rules and policies about executive remuneration. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3472 characters, which is sufficient for a detailed policy document rather than a brief announcement or certification.
2024-04-17 Chinese
2023年度独立董事述职报告（曹翠萍）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the year 2023" by an independent director of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the director's duties, attendance at board and shareholder meetings, committee work, communication with auditors, protection of investor rights, and training. The content is a narrative report on the independent director's activities and responsibilities during the year, not a financial report or an announcement of voting results or management changes. It is a specialized report related to board/management information, specifically focusing on the independent director's role and performance. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3298 characters, which is relatively short but contains substantive content about management and board activities, not just an announcement or notice.
2024-04-17 Chinese
会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is a detailed announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the company's internal policy for selecting accounting firms (auditors). It includes procedural rules, qualifications, supervisory responsibilities, and disciplinary measures related to the appointment and replacement of auditors. The document is not an audit report itself, nor is it an annual or interim financial report. It is not a certification or a brief announcement but a comprehensive governance-related policy document. The content focuses on governance practices related to auditor selection, which aligns with governance information about internal rules and board procedures. Therefore, the document best fits the category of Governance Information (CGR). The document length (4718 characters) and detailed procedural content support this classification with high confidence.
2024-04-17 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.